Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a…

• AA
  Alzheimer's Association
• EL
  Eli Lilly and Company
• B
  Biogen
• AC
  American College of Radiology
• EA
  European Association of Nuclear Medicine
• CT
  Cerveau Technologies
• NI
  National Institute for Health and Care Research

  Award: 115952
• UC
  University College London
• IM
  Innovative Medicines Initiative

  Award: 115952
• SH
  Siemens Healthineers
• CF
  Centers for Medicare and Medicaid Services
• AR
  Avid Radiopharmaceuticals
• UB
  UCLH Biomedical Research Centre
• UC
  University College London Hospitals Biomedical Research Centre